A national audit of the management of HIV-2 in adults in the UK

Abstract

Background HIV-2 is rare in the UK. Many UK centres therefore only treat small numbers of people and there are few clinical trials to guide treatment. The British HIV Association (BHIVA) 2010 guidelines for management of HIV-2 formed the basis for this national audit, which aims to describe current practice and adherence to guidelines. Methods All UK centres providing HIV care were contacted via the BHIVA “Members Matters” newsletter, and asked to submit anonymised, retrospective data for individuals living with HIV-2 accessing care at their service. Results Thirty-five sites responded and data were analysed for 167 individuals. Nearly half of individuals accessed care at one of four large London centres (77/167, 46%). Most people living with HIV-2 have taken antiretroviral therapy (ART) (132/167, 79%). The most common reasons for initiating treatment were clinical disease (34/89, 38%) and pregnancy (11/89, 12%). Most treatment-naïve individuals were initiated on a protease inhibitor based regimen (70/89, 79%). The use of integrase strand transfer inhibitor based regimens has increased over time. A significant minority of patients did not have baseline drug resistance testing performed, despite having a detectable viral load (15/52, 29%). Virological failure occurred in a minority of individuals (21/132, 16%); the most common drug regimen change in this context was the addition of an integrase strand transfer inhibitor (12/26 regimen changes, 46%). Conclusions Most individuals living with HIV-2 were managed according to national guidance, with key areas for improvement including the choice of ART, drug resistance testing and the management of virological failure. It is hoped that this national audit, performed in conjunction with the updated 2021 BHIVA guidelines will improve the care of individuals living with HIV-2 in the UK.

The slowdown of new infections by human retroviruses has reached a plateau in Spain

“…7 In Europe, infection with distinct human retroviruses is well documented. Whereas a disproportionate number of HTLV-1 and HIV-2 infections in European countries are diagnosed in migrants from the respective endemic regions, 6,[8][9][10][11] infections with HIV-1 and HTLV-2 are preferentially diagnosed in European natives, being T A B L E 1 Main epidemiological features of global human retroviral epidemics.…”